Barinthus Biotherapeutics plc
BRNS
$0.7815
-$0.0415-5.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,766.46% | 106.21% | -100.00% | -98.89% | -98.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,766.46% | 106.21% | -100.00% | -98.89% | -98.21% |
| Cost of Revenue | 13.24% | -44.11% | -65.72% | -71.70% | -75.40% |
| Gross Profit | 134.26% | 118.59% | 41.48% | -3.24% | -453.99% |
| SG&A Expenses | -40.67% | -13.15% | -18.53% | 125.39% | 501.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.29% | -17.80% | -12.70% | 40.48% | 71.60% |
| Operating Income | 43.10% | 28.12% | -5.25% | -209.73% | -2,781.61% |
| Income Before Tax | 19.99% | 28.00% | -10.11% | -274.18% | -9,102.59% |
| Income Tax Expenses | 98.57% | 79.71% | 66.24% | 37.05% | 31.22% |
| Earnings from Continuing Operations | 16.70% | 25.14% | -16.14% | -357.12% | -1,480.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.00% | -28.57% | 30.00% | 109.52% | 376.19% |
| Net Income | 16.73% | 25.14% | -16.12% | -357.79% | -1,473.03% |
| EBIT | 43.10% | 28.12% | -5.25% | -209.73% | -2,781.61% |
| EBITDA | 44.79% | 29.52% | -3.94% | -217.54% | -4,577.29% |
| EPS Basic | 18.88% | 26.76% | -14.03% | -355.30% | -1,412.77% |
| Normalized Basic EPS | 44.88% | 29.96% | -7.49% | -271.65% | -8,419.33% |
| EPS Diluted | 19.01% | 26.67% | -14.27% | -340.98% | -1,569.17% |
| Normalized Diluted EPS | 44.88% | 29.96% | -7.15% | -260.76% | -27,831.11% |
| Average Basic Shares Outstanding | 2.51% | 2.31% | 2.59% | 2.99% | 3.05% |
| Average Diluted Shares Outstanding | 2.51% | 2.31% | 1.98% | 1.72% | 0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |